MARTINSRIED / MUENCHEN, GERMANY--(Marketwire - February 18, 2010) -
MorphoSys AG / Invitation to Year End 2009 and Q4 Results Conference Call of MorphoSys AG on February 25, 2010 processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its Annual Financial Results 2009 on February 25, 2010 at 7:00 a.m. CET.
MorphoSys will hold its Analyst and Press Conference at the Hotel “Hessischer Hof” in Frankfurt, Germany. Additionally, the Management Team of MorphoSys AG will host a conference call and audio webcast to present MorphoSys’s Annual Financial Results 2009 and provide an outlook for 2010.
DATE: Thursday, 25(th) February 2010 TIME: 14:00 p.m. CET
DIAL IN No: +49 (0) 89 2444 329 75 (listen-only)
UK RESIDENTS: +44 (0) 20 3003 2666
US RESIDENTS: +1 212 999 6659
The call will be hosted by:
Dr. Simon Moroney, Chief Executive Officer
Dr. Arndt Schottelius, Chief Development Officer
Dave Lemus, Chief Financial Officer
We request that you call the number above up to 10 minutes early to ensure a prompt start and a secure line.
MorphoSys AG offers participants the opportunity to follow the presentation through a simultaneous slide presentation online at http://www.morphosys.com
The presentation slides will be available on the Company’s website.
A slide-synchronized audio replay of the conference will be available following the live event on www.morphosys.com
In case of any further questions please contact:
MorphoSys AG
Lena-Christ-Str. 48
82152 Martinsried/Planegg
Tel: +49 89 899 27 0
Fax: + 49 89 899 27 222
http://www.morphosys.com
Dr. Claudia Gutjahr-Loeser
Head of Corporate Communications & Investor Relations
Tel: +49 89 899 27-122
Fax: + 49 89 899 27-5122
gutjahr-loeser@morphosys.com
Mario Brkulj
Senior Manager Corporate Communications & Investor Relations
Tel: +49 (0) 89 / 899 27-454
Fax: +49 (0) 89 / 899 27-5454
brkulj@morphosys.com
About MorphoSys: MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company’s HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world’s leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM-CSF, is currently tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol “MOR”. For further information, visit http://www.morphosys.com/
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®) and RapMAT(®) are registered trademarks of MorphoSys AG
[HUG#1386086]
--- End of Message ---
MorphoSys AG Lena-Christ-Str. 48 Martinsried / Muenchen Germany
WKN: 663200;ISIN: DE0006632003;Index:HDAX,TECH All
Share,TecDAX,MIDCAP,CDAX,Prime All Share;
Listed: Freiverkehr in Boerse Stuttgart,
Freiverkehr in Hanseatische Wertpapierboerse zu Hamburg,
Freiverkehr in Boerse Berlin,
Freiverkehr in Boerse Duesseldorf,
Freiverkehr in Bayerische Boerse Muenchen,
Freiverkehr in Niedersaechsische Boerse zu Hannover,
Prime Standard in Frankfurter Wertpapierboerse,
Regulierter Markt in Frankfurter Wertpapierboerse;
Conference Call Alert: http://hugin.info/130295/R/1386086/344753.pdf
